Boston Scientific announced on X, formerly known as Twitter, that the U.S. Food and Drug Administration (FDA) has approved its AVVIGOTM+ Multi-Modality Guidance System. The company described AVVIGOTM+ as a “next-generation PCI guidance system,” saying it “enhances the [intravascular imaging] and coronary physiology experience to help improve patient outcomes.” For more information about the device, click here.